Mission Bio announces its 1st single-cell Tapestri Center of Excellence

By The Science Advisory Board staff writers

March 2, 2022 -- Mission Bio has announced its first Center of Excellence, located at Memorial Sloan Kettering Cancer Center (MSK). As the first single-cell Tapestri Center of Excellence for solid tumor research, the lab will drive academic and industrial best practices using single-cell DNA profiling to observe tumor heterogeneity and clonal architecture in solid cancers.

Using Mission Bio's single-cell DNA sequencing technology, the center of excellence researchers revealed a co-occurrence of secondary driver mutations in cells carrying the KRAS (G12C) mutation, allowing them to circumvent and resist targeted therapy. This represents an important insight into one of the most promising new drugs in solid tumors.

Tapestri is the only commercial product capable of simultaneously analyzing DNA and other analytes like cell surface proteins at the single-cell level through its unique two-step droplet microfluidics technology, according to Mission Bio. Tapestri can be used to interrogate clonal mosaicism and neoplastic transition, clonal evolution, and metastatic dissemination with its ability to co-detect SNVs and CNVs at the single-cell level in a scalable manner.

As a tool for understanding disease resistance, users can detect rare emergent clones early with reliable and sensitive loss of heterozygosity measurements to understand how driver mutations are added over time that allows tumor escape and metastasis.

Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure and predict our resistance and response to new therapies.

Researchers identify BTK inhibitor-resistant clones with Mission Bio
Mission Bio, in conjunction with researchers at Memorial Sloan Kettering Cancer Center and the University of Miami, has published new findings showing...
Mission Bio transfers 1st Tapestri GMP-ready CGT assay
Mission Bio has completed the first tech transfer of a clinical trial-, good manufacturing practices (GMP)-ready cell and gene therapy (CGT) assay from...
Mission Bio touts study about its Tapestri platform
Mission Bio announced that its Tapestri platform helped elucidate resistance mechanisms to lung cancer drugs. Researchers from Memorial Sloan Kettering...
Mission Bio debuts new capabilities for cell, gene therapy
Mission Bio has unveiled its Tapestri Cell & Gene Therapy Solutions, a new addition to its Tapesti platform that can provide analytical characterization...
Mission Bio updates platform to expand heme-onc research
Mission Bio has improved its Tapestri platform to expand its accessibility and utility in hematologic oncology (heme-onc) research.

Copyright © 2022 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter